Search

everythinglearnresearchcommunity

for

Search:↓

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The user is experiencing significant hair thinning on the front scalp while taking oral finasteride and minoxidil. They are unsure if it's androgenetic alopecia or related to seborrheic dermatitis.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.

The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.

A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It mentions a CEO becoming the first patient for HairClone.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The conversation discusses using 2% Pyrilutamide from Anagenica for hair loss, as the user did not see results with 1% Pyrilutamide. The user is considering increasing the dosage but is concerned about the cost.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation discusses the effectiveness and cost of using Hair + Me for Minoxidil, with some users suggesting buying treatments separately or from online pharmacies for savings. A user mentions a positive experience with Hair + Me for Minoxidil and Skin+Me for skincare.

Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

Essential oils like rosemary, thyme, lavender, and cedar wood in a carrier oil may effectively treat alopecia areata and potentially male pattern baldness by stimulating the scalp similarly to minoxidil. The user plans to try this routine and share results.